Why the study?
BNP can act as a biomarker in septic shock, but its elevation in other conditions limits its use as the sole prognostic marker in hospitalized sepsis patients.
Does elevated brain natriuretic peptide (BNP) predict mortality in patients hospitalized with sepsis?
Does elevated brain natriuretic peptide (BNP) predict mortality in patients hospitalized with sepsis?
While BNP has moderate predictive value for mortality in sepsis, its clinical utility as a standalone prognostic marker is limited by the lack of consensus on cut-off values and its elevation in non-sepsis conditions.
Caution against sole reliance on BNP for sepsis prognosis; leaves open its adjunctive value in integrated models.
Brain natriuretic peptide (BNP) is a neurohormone released in response to volume expansion and increased pressure. It is commonly used to assist in the diagnosis and management of heart failure. BNP can also play an important role as a biomarker in septic shock; however, elevations of BNP in conditions other than sepsis or cardiac dysfunction limits its use as the sole prognostic marker in patients hospitalized with sepsis. Further relationships regarding laboratory value and correlation with severity of illness need to be established with larger prospective studies to develop consensus regarding a cut-off point for optimum sensitivity and specificity in predicting in-hospital mortality related to sepsis.
No takes yet. Share an insight, caveat, or question.
Bhandari et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: